Onkológia 2/2022

A comprehensive view of the treatment of HER2-positive breast cancer

Recent years have brought several changes in the treatment of HER2-positive breast cancers. The intensity of research is reflected in modifications of neoadjuvant and adjuvant treatment, with a consequent shift in the treatment of relapse and metastatic disease. New drugs such as tucatinib, trastuzumab deruxtecan and margetuximab are gradually being added to treatment. Possible escalation or deescalation options of the treatment are subject of intense discussion. This review article aims to offer an up-to-date comprehensive overview of the latest data and to help improve the orientation in the treatment sequence options. Unfortunately, in the case of new drugs, we face the widening of the availability gap between the Slovak Republic and other countries of the European Union.

Keywords: HER2-positive breast cancer, systemic treatment, treatment sequence